{"id":"administration-of-dornase-alfa","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Sputum culture positive for Pseudomonas aeruginosa"},{"rate":"null","effect":"Hemoptysis"}]},"_chembl":{"chemblId":"CHEMBL1201431","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process makes it easier to cough up mucus, improving lung function and reducing the risk of respiratory complications. Dornase alfa works by degrading DNA, which is a major component of the thick, sticky mucus produced by individuals with cystic fibrosis. By breaking down DNA, dornase alfa helps to reduce the viscosity of the mucus, making it easier to clear from the lungs.","oneSentence":"Dornase alfa is a recombinant form of human deoxyribonuclease I that breaks down DNA in the extracellular matrix of cystic fibrosis sputum, reducing its viscosity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:47.447Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT07432373","phase":"","title":"Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection","status":"NOT_YET_RECRUITING","sponsor":"National University of Malaysia","startDate":"2026-04-01","conditions":"Pleural Infection","enrollment":80},{"nctId":"NCT05903417","phase":"NA","title":"Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2023-07-10","conditions":"Pleural Infection","enrollment":40},{"nctId":"NCT04785066","phase":"PHASE2","title":"Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target)","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2022-08-19","conditions":"Ischemic Stroke","enrollment":39},{"nctId":"NCT04095676","phase":"NA","title":"VATS Surgery Compared to Drainage in the Treatment of Pleural Empyema","status":"RECRUITING","sponsor":"Thomas Decker Christensen","startDate":"2022-10-30","conditions":"Pleural Empyema","enrollment":184},{"nctId":"NCT06723717","phase":"PHASE2","title":"Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months","status":"NOT_YET_RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-04","conditions":"Ruptured Aneurysm of Intracranial Artery, SAH (Subarachnoid Hemorrhage), Delayed Cerebral Ischemia","enrollment":304},{"nctId":"NCT04359654","phase":"PHASE2","title":"Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-06-16","conditions":"COVID-19 (Coronavirus Disease 2019), Hypoxia","enrollment":41},{"nctId":"NCT05880524","phase":"PHASE2","title":"Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)","status":"NOT_YET_RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2024-12","conditions":"Ischemic Stroke, Inflammatory Response","enrollment":36},{"nctId":"NCT03213834","phase":"PHASE4","title":"Fibrinolytic Therapy Versus Medical Thoracoscopy","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-09-14","conditions":"Pleural Diseases","enrollment":5},{"nctId":"NCT04320381","phase":"","title":"Qualitative Understanding of Experiences With the SIMPLIFY Trial","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2020-12-23","conditions":"Cystic Fibrosis, Drug Withdrawal","enrollment":115},{"nctId":"NCT05279391","phase":"NA","title":"Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19","status":"UNKNOWN","sponsor":"Democritus University of Thrace","startDate":"2020-10-25","conditions":"COVID-19 Severe Respiratory Failure","enrollment":150},{"nctId":"NCT04355364","phase":"PHASE3","title":"Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2020-04-21","conditions":"COVID-19, Acute Respiratory Distress Syndrome","enrollment":77},{"nctId":"NCT04445285","phase":"PHASE2","title":"Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure","status":"RECRUITING","sponsor":"Jon Simmons","startDate":"2020-04-28","conditions":"Covid19","enrollment":44},{"nctId":"NCT04402970","phase":"PHASE3","title":"Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2020-06-19","conditions":"SARS-CoV 2, ARDS","enrollment":30},{"nctId":"NCT02135588","phase":"PHASE1","title":"Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions","status":"UNKNOWN","sponsor":"Eastern Regional Medical Center","startDate":"2013-10","conditions":"Loculated or Non-draining Malignant Pleural Effusions","enrollment":10},{"nctId":"NCT04459325","phase":"PHASE3","title":"Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2020-06-01","conditions":"COVID-19, Coronavirus Disease 2019","enrollment":100},{"nctId":"NCT04432987","phase":"PHASE2","title":"Dornase Alpha for the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Acibadem University","startDate":"2020-05-25","conditions":"COVID-19","enrollment":60},{"nctId":"NCT01717742","phase":"PHASE3","title":"Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2012-12","conditions":"Pleural Empyema","enrollment":97},{"nctId":"NCT02193490","phase":"PHASE1, PHASE2","title":"DNase Treatment for Dry Eyes","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2014-07","conditions":"Dry Eye","enrollment":47},{"nctId":"NCT03586076","phase":"PHASE1","title":"A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects","status":"COMPLETED","sponsor":"JHL Biotech, Inc.","startDate":"2018-01-26","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT00419380","phase":"PHASE4","title":"Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-01","conditions":"Otitis Media","enrollment":40},{"nctId":"NCT02168387","phase":"PHASE4","title":"Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient","status":"COMPLETED","sponsor":"Duke University","startDate":"2010-12","conditions":"Atelectasis","enrollment":39},{"nctId":"NCT00416182","phase":"PHASE2","title":"Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2006-12","conditions":"Sinusitis, Cystic Fibrosis","enrollment":16},{"nctId":"NCT00557089","phase":"PHASE4","title":"The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2008-01","conditions":"Cystic Fibrosis","enrollment":17},{"nctId":"NCT01095276","phase":"NA","title":"Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-11","conditions":"Atelectasis, Ventilation, Mechanical","enrollment":30},{"nctId":"NCT00502632","phase":"PHASE2, PHASE3","title":"Dornase Alfa and Urokinase for Kids With Pleural Empyema","status":"UNKNOWN","sponsor":"Azienda Ospedaliera di Padova","startDate":"2007-10","conditions":"Pleural Empyema","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":147,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Administration of dornase alfa","genericName":"Administration of dornase alfa","companyName":"Fondation Ophtalmologique Adolphe de Rothschild","companyId":"fondation-ophtalmologique-adolphe-de-rothschild","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dornase alfa is a recombinant form of human deoxyribonuclease I that breaks down DNA in the extracellular matrix of cystic fibrosis sputum, reducing its viscosity. Used for Cystic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}